🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHeart rate increase on GLP-1 — November 2025

Heart rate increase on GLP-1 — November 2025

Dr.ObesityMed Thu, May 30, 2024 at 5:58 AM 31 replies 2,498 viewsPage 1 of 7
This thread is more than 24 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
May 30, 2024 at 5:58 AM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Relative versus absolute is the distinction that gets lost: a 20% relative reduction on a high baseline risk is a large absolute benefit, and the same relative figure on a low baseline risk is a small one.

So the question, as narrowly as I can put it: how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

39 9EndoResFellow, PharmacoVig_BOS, SurmountFan_IN and 36 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
May 30, 2024 at 6:04 AM#2
Dr.ObesityMed said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
38 8kim_atl_prep, sarah_TO, wendy_avl and 35 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
May 30, 2024 at 6:10 AM#3
Dr.SleepRoch said:
Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated…

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 4 of 5 diagnostic criteria to meeting ZERO after 12 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 51" → 37" ✅ Resolved
  2. Triglycerides: 247 → 107 ✅ Resolved
  3. HDL: 35 → 59 ✅ Resolved
  4. Blood pressure: 147/93 → 120/74 ✅ Resolved
  5. Fasting glucose: 127 → 87 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

Last edited: May 30, 2024 at 12:10 PM
37 7james_edin, FranDenver, Dr.BariatricHTX and 34 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
JessicaM_2024
Member
823
3,456
Mar 2024
Portland, OR
May 30, 2024 at 6:16 AM#4
Dr.ObesityMed said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

This matches mine closely enough to be worth saying so out loud. Posting only so the count is not one.

36 6Dr.PainCLE, mike_mealprep, NicoleRaleigh and 33 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
May 30, 2024 at 6:45 AM#5

From the other side of the consultation, briefly.

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

35 5lori_vegas, Dr.PulmRoch, maya_sedona and 32 others
Reply Quote Save Share Report
1237

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register